245 related articles for article (PubMed ID: 17851879)
1. Accuracy of MRI for estimating residual tumor size after neoadjuvant chemotherapy in locally advanced breast cancer: relation to response patterns on MRI.
Kim HJ; Im YH; Han BK; Choi N; Lee J; Kim JH; Choi YL; Ahn JS; Nam SJ; Park YS; Choe YH; Ko YH; Yang JH
Acta Oncol; 2007; 46(7):996-1003. PubMed ID: 17851879
[TBL] [Abstract][Full Text] [Related]
2. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer.
Gajdos C; Tartter PI; Estabrook A; Gistrak MA; Jaffer S; Bleiweiss IJ
J Surg Oncol; 2002 May; 80(1):4-11. PubMed ID: 11967899
[TBL] [Abstract][Full Text] [Related]
3. Magnetic resonance imaging and ultrasonography in predicting infiltrating residual disease after preoperative chemotherapy in stage II-III breast cancer.
Guarneri V; Pecchi A; Piacentini F; Barbieri E; Dieci MV; Ficarra G; Tazzioli G; Frassoldati A; Battista R; Canossi B; Mauri C; D'Amico R; Conte P; Torricelli P
Ann Surg Oncol; 2011 Aug; 18(8):2150-7. PubMed ID: 21301969
[TBL] [Abstract][Full Text] [Related]
4. MRI evaluation of residual tumor size after neoadjuvant endocrine therapy vs. neoadjuvant chemotherapy.
Takeda K; Kanao S; Okada T; Ueno T; Toi M; Ishiguro H; Mikami Y; Tanaka S; Togashi K
Eur J Radiol; 2012 Sep; 81(9):2148-53. PubMed ID: 21664779
[TBL] [Abstract][Full Text] [Related]
5. Meta-analysis of magnetic resonance imaging in detecting residual breast cancer after neoadjuvant therapy.
Marinovich ML; Houssami N; Macaskill P; Sardanelli F; Irwig L; Mamounas EP; von Minckwitz G; Brennan ME; Ciatto S
J Natl Cancer Inst; 2013 Mar; 105(5):321-33. PubMed ID: 23297042
[TBL] [Abstract][Full Text] [Related]
6. MRI staging after neoadjuvant chemotherapy for breast cancer: does tumor biology affect accuracy?
McGuire KP; Toro-Burguete J; Dang H; Young J; Soran A; Zuley M; Bhargava R; Bonaventura M; Johnson R; Ahrendt G
Ann Surg Oncol; 2011 Oct; 18(11):3149-54. PubMed ID: 21947592
[TBL] [Abstract][Full Text] [Related]
7. Change in tumor cellularity of breast carcinoma after neoadjuvant chemotherapy as a variable in the pathologic assessment of response.
Rajan R; Poniecka A; Smith TL; Yang Y; Frye D; Pusztai L; Fiterman DJ; Gal-Gombos E; Whitman G; Rouzier R; Green M; Kuerer H; Buzdar AU; Hortobagyi GN; Symmans WF
Cancer; 2004 Apr; 100(7):1365-73. PubMed ID: 15042669
[TBL] [Abstract][Full Text] [Related]
8. Computer-aided detection applied to breast MRI: assessment of CAD-generated enhancement and tumor sizes in breast cancers before and after neoadjuvant chemotherapy.
Demartini WB; Lehman CD; Peacock S; Russell MT
Acad Radiol; 2005 Jul; 12(7):806-14. PubMed ID: 16039534
[TBL] [Abstract][Full Text] [Related]
9. Contrast enhanced magnetic resonance imaging underestimates residual disease following neoadjuvant docetaxel based chemotherapy for breast cancer.
Denis F; Desbiez-Bourcier AV; Chapiron C; Arbion F; Body G; Brunereau L
Eur J Surg Oncol; 2004 Dec; 30(10):1069-76. PubMed ID: 15522553
[TBL] [Abstract][Full Text] [Related]
10. Accuracy of MRI for treatment response assessment after taxane- and anthracycline-based neoadjuvant chemotherapy in HER2-negative breast cancer.
Charehbili A; Wasser MN; Smit VT; Putter H; van Leeuwen-Stok AE; Meershoek-Klein Kranenbarg WM; Liefers GJ; van de Velde CJ; Nortier JW; Kroep JR
Eur J Surg Oncol; 2014 Oct; 40(10):1216-21. PubMed ID: 25150151
[TBL] [Abstract][Full Text] [Related]
11. Residual Mammographic Microcalcifications and Enhancing Lesions on MRI After Neoadjuvant Systemic Chemotherapy for Locally Advanced Breast Cancer: Correlation with Histopathologic Residual Tumor Size.
Kim YS; Chang JM; Moon HG; Lee J; Shin SU; Moon WK
Ann Surg Oncol; 2016 Apr; 23(4):1135-42. PubMed ID: 26628432
[TBL] [Abstract][Full Text] [Related]
12. Accuracy of clinical examination, digital mammogram, ultrasound, and MRI in determining postneoadjuvant pathologic tumor response in operable breast cancer patients.
Croshaw R; Shapiro-Wright H; Svensson E; Erb K; Julian T
Ann Surg Oncol; 2011 Oct; 18(11):3160-3. PubMed ID: 21947594
[TBL] [Abstract][Full Text] [Related]
13. Clinical and radiologic assessments to predict breast cancer pathologic complete response to neoadjuvant chemotherapy.
Schott AF; Roubidoux MA; Helvie MA; Hayes DF; Kleer CG; Newman LA; Pierce LJ; Griffith KA; Murray S; Hunt KA; Paramagul C; Baker LH
Breast Cancer Res Treat; 2005 Aug; 92(3):231-8. PubMed ID: 16155794
[TBL] [Abstract][Full Text] [Related]
14. Pure and predominantly pure intralymphatic breast carcinoma after neoadjuvant chemotherapy: an unusual and adverse pattern of residual disease.
Rabban JT; Glidden D; Kwan ML; Chen YY
Am J Surg Pathol; 2009 Feb; 33(2):256-63. PubMed ID: 18936689
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of pathological response of primary tumor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma.
Machiavelli MR; Romero AO; Pérez JE; Lacava JA; Domínguez ME; Rodríguez R; Barbieri MR; Romero Acuña LA; Romero Acuña JM; Langhi MJ; Amato S; Ortiz EH; Vallejo CT; Leone BA
Cancer J Sci Am; 1998; 4(2):125-31. PubMed ID: 9554929
[TBL] [Abstract][Full Text] [Related]
16. Accuracy of MR imaging for revealing residual breast cancer in patients who have undergone neoadjuvant chemotherapy.
Partridge SC; Gibbs JE; Lu Y; Esserman LJ; Sudilovsky D; Hylton NM
AJR Am J Roentgenol; 2002 Nov; 179(5):1193-9. PubMed ID: 12388497
[TBL] [Abstract][Full Text] [Related]
17. Combined use of MRI and PET to monitor response and assess residual disease for locally advanced breast cancer treated with neoadjuvant chemotherapy.
Chen X; Moore MO; Lehman CD; Mankoff DA; Lawton TJ; Peacock S; Schubert EK; Livingston RB
Acad Radiol; 2004 Oct; 11(10):1115-24. PubMed ID: 15530804
[TBL] [Abstract][Full Text] [Related]
18. Accuracy of MRI in the detection of residual breast cancer after neoadjuvant chemotherapy.
Rosen EL; Blackwell KL; Baker JA; Soo MS; Bentley RC; Yu D; Samulski TV; Dewhirst MW
AJR Am J Roentgenol; 2003 Nov; 181(5):1275-82. PubMed ID: 14573420
[TBL] [Abstract][Full Text] [Related]
19. Role of diffusion-weighted imaging as an adjunct to contrast-enhanced breast MRI in evaluating residual breast cancer following neoadjuvant chemotherapy.
Hahn SY; Ko EY; Han BK; Shin JH; Ko ES
Eur J Radiol; 2014 Feb; 83(2):283-8. PubMed ID: 24315957
[TBL] [Abstract][Full Text] [Related]
20. Analysis of factors that influence the accuracy of magnetic resonance imaging for predicting response after neoadjuvant chemotherapy in locally advanced breast cancer.
Ko ES; Han BK; Kim RB; Ko EY; Shin JH; Hahn SY; Nam SJ; Lee JE; Lee SK; Im YH; Park YH
Ann Surg Oncol; 2013 Aug; 20(8):2562-8. PubMed ID: 23463090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
